Latest Breaking News On - European society of medical oncology congress - Page 7 : comparemela.com

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

FOSTER CITY, Calif., Oct. 23, 2023 Apollomics Inc. , today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the European Society of Medical.

United statesGuo liang yuSean leousPeter vozzoPearl biotechnology ltdEuropean society of medical oncology congressSecurities exchangeApollomics incAvistone biotechnology ltdEuropean societyMedical oncology congressNon small cell lung cancerChief executive officerApollomic chinaAvistone biotechnologyBeijing pearl biotechnology ltd

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation

FOSTER CITY, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) Apollomics Inc. (Nasdaq: APLM ) (the “Company”), today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical

United statesGuo liang yuSean leousPeter vozzoApollomics incEuropean society of medical oncology congressAvistone biotechnology ltdPearl biotechnology ltdSecurities exchangeEuropean societyMedical oncology congressNon small cell lung cancerChief executive officerApollomic chinaAvistone biotechnologyBeijing pearl biotechnology ltd

Kazia Therapeutics Limited Announces Clinical Data At ESMO 2023 from Ongoing Phase 1 ESMO Study

Kazia Therapeutics Limited announced that selected clinical data from the company s ongoing Phase 1 clinical trial evaluating EVT801 in patients with advanced solid tumours was presented at the.

Carlosa gomez rocaEuropean society of medical oncology congressKazia therapeuticsKazia therapeutics limitedEuropean societyMedical oncology congressToulouse france

KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY

SYDNEY, Oct. 23, 2023 /PRNewswire/ Kazia Therapeutics Limited , an oncology-focused drug development company, announces that selected clinical data from the company s ongoing Phase 1 clinical.

New south walesUnited statesCarlosa gomez rocaJohn friendKazia therapeuticsDrug administrationEuropean society of medical oncology congressKazia therapeutics limitedExchange commissionEuropean societyMedical oncology congressToulouse franceChief executive officerTherapeutics limitedOrphan drugFast track designation

Amgen sticks by Lumakras dose as ESMO data boost confidence

Amgen sticks by Lumakras dose as ESMO data boost confidence
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Paul burtonEuropean society of medical oncology congressAmgen chief medical officer paul burtonEuropean societyMedical oncology congress